True innovation in healthcare requires us to look beyond the obvious. For years, DNA sequencing has been the key pillar of precision medicine, offering insights into disease predispositions, mechanisms, and diagnosis that inform treatment.
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer.
